Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study	Diagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract	Not yet recruiting	Phase 2	2026-08-26		NCT07788365

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
University Hospital, Strasbourg, France	263

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hôpitaux Universitaires de Strasbourg	Strasbourg	France	16

Clinical trials